Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer

// Sabina Pucci 1, * , Maria Josè Zonetti 1 , Tommaso Fisco 1 , Chiara Polidoro 1 , Gianfranco Bocchinfuso 2 , Antonio Palleschi 2 , Giuseppe Novelli 1 , Luigi G. Spagnoli 1 , Paola Mazzarelli 1, * 1 Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy 2 Department of Chemical Sciences and Technologies, Tor Vergata University of Rome, Rome, Italy * These authors have contributed equally to this work Correspondence to: Luigi G. Spagnoli, e-mail: spagnoli@alleanzacontroilcancro.it Sabina Pucci, e-mail: sabina.pucci@uniroma2.it Keywords: breast cancer, carnitine palmitoyl transferase-1A, HDAC inhibitor, tumor metabolism, tumor specific target Received: July 28, 2015      Accepted: January 01, 2016      Published: January 21, 2016 ABSTRACT Transcriptional mechanisms epigenetically-regulated in tumoral tissues point out new targets for anti-cancer therapies. Carnitine palmitoyl transferase I (CPT1) is the rate-limiting enzyme in the transport of long-chain fatty acids for β-oxidation. Here we identified the tumor specific nuclear CPT1A as a product of the transcript variant 2, that doesn’t retain the classical transferase activity and is strongly involved in the epigenetic regulation of cancer pro-survival, cell death escaping and tumor invasion pathways. The knockdown of CPT1A variant 2 by small interfering RNAs (siRNAs), was sufficient to induce apoptosis in MCF-7, SK-BR3 and MDA-MB-231 breast cancer cells. The cell death triggered by CPT1A silencing correlated with reduction of HDAC activity and histone hyperacetylation. Docking experiments and molecular dynamics simulations confirmed an high binding affinity of the variant 2 for HDAC1. The CPT1A silenced cells showed an up-regulated transcription of pro-apoptotic genes (BAD, CASP9, COL18A1) and down-modulation of invasion and metastasis related-genes (TIMP-1, PDGF-A, SERPINB2). These findings provide evidence of the CPT1 variant 2 involvement in breast cancer survival, cell death escape and invasion. Thus, we propose nuclear CPT1A as a striking tumor specific target for anticancer therapeutics, more selective and effective as compared with the well-known HDAC inhibitors.